Core Insights - DexCom's shares declined nearly 3% on June 3 due to rising competition following the FDA's approval of Abbott's competing product Lingo [1][2] - DexCom's Stelo, approved in March 2024, is the first over-the-counter continuous glucose monitoring (CGM) device, allowing users to track glucose levels via smartphone without a prescription [1][4] - Abbott's Lingo, also an over-the-counter glucose monitor, is already available in the UK and poses a competitive threat to DexCom in the OTC CGM market [2][4] Company Performance - DexCom's shares have decreased by 7.2% year-to-date, contrasting with a 5% growth in the industry and a 10.9% rise in the S&P 500 Index [3] - The company has seen strong contributions from its Sensor segment and growth in both domestic and international revenues, which are expected to continue through 2024 [7] Competitive Landscape - Both DexCom and Abbott compete in the CGM market with their respective devices, G6 & G7 and Libre, but the new OTC devices Stelo and Lingo target a broader audience, including non-diabetic individuals [4][5] - Abbott's extensive resources in healthcare product markets may provide it with a competitive edge over DexCom as both companies launch their OTC products [5][6] Notable Developments - DexCom announced compatibility of its G6 and G7 CGM sensors with Tandem Diabetes Care's Mobi insulin pump, enhancing predictive capabilities for glucose levels [7] - A new feature allowing direct connection of the G7 CGM to Apple Watch is set to launch gradually by the end of Q2 2024, potentially increasing user convenience [8]

Shares of DexCom (DXCM) lost almost 3% on Jun 3, probably due to concerns about a rise in competition for its recently approved Stelo as the FDA approved a competing product.The FDA approval for Stelo in March 2024 looked promising as it was the first and only continuous glucose monitoring (CGM) device to receive approval for its over-the-counter (OTC) availability as a glucose biosensor. Stelo represents a significant opportunity as it can be used to get glucose insights directly on a smartphone without a ...

Innovation is paying off for both of these medical device specialists.Every good thing must come to an end -- and, eventually, the bull market we're experiencing will, too. Long-term investors must prepare for that to happen at some point.One of the best ways to do so is to buy stocks that can perform well through bull runs but can also hold down the fort when things aren't going so well. That's what it takes to deliver market-beating returns over long periods -- corporations that crumble under the pressure ...

Vertex might not present a clear and present danger to Abbott and DexCom but could present a clear future threat.Successful investors think about the future by focusing on what the new opportunities might be. They also pay attention to threats that could emerge that might impact the stocks they own. Sometimes, those threats come out of the blue, but other times, they're identifiable well in advance.If you own shares of Abbott (ABT -1.20%) or DexCom (DXCM 0.20%), there's a looming threat to know about. It's ...

In a recent deep-dive research report on the state of the MedTech (medical technology) sector, Oppenheimer highlighted the potential of artificial intelligence (AI) in the sector, noting its capacity to save an estimated $200 billion to $300 billion annually through enhanced workflow management. Inspired by these findings, this article explores the three best MedTech stocks to buy now, each poised to capitalize on AI-driven advancements.The promise of AI in MedTech is substantial with workflow efficiency im ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium includes access to the Zacks Style Scores as we ...

Core Viewpoint - DexCom, Inc. (DXCM) is positioned for growth due to its strong product portfolio and favorable coverage decisions, despite facing competition risks [1] Group 1: Financial Performance - DexCom's shares have increased by 6.3% year to date, while the industry has grown by 10% and the S&P 500 Index by 11.5% [1] - The company has a market capitalization of $51.58 billion and projects a 33% growth over the next five years [1] - In the first quarter of 2024, DexCom's earnings per share improved by 88.2% year over year to 32 cents, with revenues up 24% at $921 million [5] - The company raised its revenue guidance for 2024 to a range of $4.2-$4.35 billion, indicating organic growth of 17-21% year over year [5] - The Zacks Consensus Estimate for earnings per share for 2024 has increased from $1.75 to $1.78, with second-quarter revenue estimates at $1.04 billion, reflecting a 19.1% improvement year over year [7] Group 2: Product Development and Market Opportunities - DexCom continues to expand its product portfolio with new products like G7 and One+, which have driven growth [2] - The G7 sensor has shown strong demand since its launch, and the company is focusing on connecting CGM sensors with automated insulin delivery systems [2] - The glucose monitoring market offers significant commercial opportunities, including non-intensive diabetes management and obesity [3] - The FDA approved a new glucose sensor, Stelo, for type II diabetes, expected to launch in the U.S. in summer 2024, which is anticipated to be a key growth driver [3] Group 3: Coverage and Competitive Position - DexCom's G6 and G7 sensors have received extensive coverage in the U.S., bolstered by the Centers for Medicare & Medicaid Services' decision to expand coverage for insulin users and certain non-insulin users [4] - The G7 CGM System is covered by all major pharmacy benefit managers in the U.S., and DexCom One+ is available in Europe under a reimbursement policy [5] - The company is recognized as the most covered CGM in the U.S., enhancing its competitive position [4]

SHANGHAI, CHINA - JANUARY 25, 2022 - A 3M logo display of air-condensed thermal materials in a ... [+] shopping mall in Shanghai, China, January 25, 2022. (Photo credit should read Wang Gang / Costfoto/Future Publishing via Getty Images)Future Publishing via Getty ImagesGiven its better prospects, we believe DexCom stock (NASDAQ NASDAQ : DXCM) is a better pick than 3M stock (NYSE: MMM). Although these companies are from different sectors, we compare them because of their similar market capitalization of aro ...

Willie B. Thomas/DigitalVision via Getty Images Investment action I recommended a buy rating for Dexcom (NASDAQ:DXCM) when I wrote about it during October last year, as the 3Q23 results gave me further confidence in the business's positive outlook. The share price has rallied strongly post-my update, back to as high as DXCM’s 1-year all-time high of $142 (~10% below my target price). Based on my current outlook and analysis, I recommend a buy rating. My key update to my thesis is that DXCM should contin ...

Editor's note: Seeking Alpha is proud to welcome Nicholas Sylvia as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium access. Click here to find out more » JHVEPhoto I believe that DexCom is undervalued and that a price correction could occur within the next 12 months for the following reasons: Manufacturing Consolidation - I believe DexCom has the ability to s ...